Cited by 92Retinal Diseases and TreatmentsRetinal Imaging and AnalysisAngiogenesis and VEGF in Cancer

Microvascular complications and diabetic retinopathy: recent advances and future implications

Open access
Barot, Megha, Gokulgandhi, Mitan R, Patel, Sulabh, Mitra, Ashim K·2013·Future Medicinal Chemistry

Abstract

Retinal microvascular alterations have been observed during diabetic retinopathy (DR) due to the retinal susceptibility towards subtle pathological alterations. Therefore, retinal microvascular pathology is essential to understand the nature of retinal degenerations during DR. In this review, the role of retinal microvasculature complications during progression of DR, along with recent efforts to normalize such alterations for better therapeutic outcome, will be underlined. In addition, current therapeutics and future directions for advancement of standard treatment for DR patients will be discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4155/fmc.12.206

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neovascularization is the predominant pathology in various blinding disorders including wet AMD, ME and proliferative DR.

    “Neovascularization is the predominant pathology in various blinding disorders including wet age-related macular degeneration (AMD), macular edema (ME) and proliferative diabetic retinopathy (DR) [164].”

    From From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics (2025) · cites this paper as [164]

    The Abstract (page unavailable) defines proliferative diabetic retinopathy by the growth of abnormal new blood vessels, and the Anti-VEGF therapy section discusses neovascular AMD. But the paper lists macular edema and neovascularization as separate abnormalities and does not establish neovascularization as the predominant pathology of macular edema. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Barot, M., Gokulgandhi, M. R., Patel, S., & Mitra, A. K.
Affiliations
University of Missouri–Kansas City (US)
Venue
Future Medicinal Chemistry
Published
2013-03
Volume
5
Issue
3
Pages
301-314
ISSN
  • 1756-8919 (ISSN-L)
  • 1756-8927
OpenAlex
W2158855079
Cited by
92
References
137
Citations by year
2026: 3 · 2025: 10 · 2024: 12 · 2023: 3 · 2022: 16 · 2021: 11 · 2020: 8 · 2019: 6 · 2018: 8 · 2017: 2 · 2016: 6 · 2015: 5 · 2014: 2
FWCI
0.76
Type
journal article
Language
en
Open access
Locations
  • Future Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (RO1 EY 09171–16 and RO1 EY 10659–14)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
diabetic retinopathy, retinal microvasculature, microvascular complications, retinal degeneration, diabetic retinopathy progression
MeSH terms
Animals, Antioxidants, Diabetic Retinopathy, Humans, Mitochondria, Retina, Retinal Vessels, Steroids, Vascular Endothelial Growth Factor A, Protein Kinase Inhibitors, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review